This flowchart guides healthcare professionals through a smoking cessation conversation, from asking whether a person is ready to quit to planning follow-up. It brings together the 5 A’s, the 5 R’s, nicotine dependence assessment, behavioural support, and medication options.
If the person is ready to quit, use the 5 A’s to assess their needs, assist with a quit plan, and arrange follow-up. The Fagerström Test for Nicotine Dependence (FTND) can help assess cigarette dependence and inform the treatment discussion.
If the person is not ready to quit, use the 5 R’s to explore why quitting might matter to them, what could make it difficult, and when to revisit the conversation.
When discussing treatment, consider the person’s preferences, health history, current medicines, and previous quit attempts. Offer behavioural support and discuss whether a smoking cessation medicine is suitable.
At follow-up, ask what helped and what was difficult. If the person has returned to smoking, use what they learned to shape the next attempt
Close
Ask about tobacco use. Identify and document tobacco use status for every patient at every visit.
Advise quitting. At every visit, urge each patient who uses tobacco to quit. Give clear, strong advice tailored to the patient.
Assess willingness to make a quit attempt. Ask whether the patient is willing to try quitting now.
Assist with the quit attempt. For patients willing to try, offer medication and provide counselling or refer them for counselling or additional treatment.
Arrange follow-up. Begin within the first week after the quit date and continue over the next 12 months. Address relapse risk and help if relapse occurs. If the patient is unwilling to try quitting now, revisit tobacco dependence and willingness to quit at the next clinic visit.
Relevance. Ask why quitting matters to the patient personally.
Risks. Discuss the patient’s health risks if they continue using tobacco.
Rewards. Explain the health benefits the patient could gain by quitting.
Roadblocks. Ask what might make quitting difficult.
Repetition. Revisit the discussion at future visits, regardless of whether the patient is willing to quit today.
Review these patient characteristics when discussing smoking cessation and treatment options.
Age and preferences
Medical history and coexisting conditions, including cardiovascular and psychiatric conditions
Allergies and intolerances
Pregnancy or breastfeeding
Previous quit attempts, including what made quitting difficult, cravings and withdrawal symptoms
Current medicines and possible drug interactions
Alcohol or other drug use
Concerns about weight gain
Medicines can help you quit smoking. Counselling or Quitline support can improve your chances of quitting. Ask a pharmacist or doctor which option and dose suit you.
Nicotine patch, gum and lozenge
Patch: Releases nicotine steadily through the skin to ease withdrawal.
Gum or lozenge: Works faster for cravings. Chew and park the gum between your cheek and gum. Let the lozenge dissolve slowly.
Combination NRT: A patch plus a faster-acting product can work better than one form alone.
Quit guide to combination nicotine replacement therapy
Nicotine mouth spray and varenicline
Nicotine mouth spray: A fast-acting option for cravings. It is sprayed into the mouth.
Varenicline: A prescription tablet that helps reduce cravings and withdrawal. Ask your prescriber about side effects and whether it suits you.
Australian nicotine inhalators have been discontinued. The nasal spray in the original table is a different product from the mouth spray.
Quit guide to nicotine replacement therapy · TGA information on varenicline
Bupropion SR
A sustained-release prescription tablet that can help with quitting smoking. It can interact with other medicines and is unsuitable for people with a history of seizures. Your prescriber can check whether it suits you.
TGA consumer and product information for Zyban SR
Cytisine
Cytisine is a tablet used to help adults quit smoking. Cyventine is registered in Australia and comes as a 25-day course. Ask your pharmacist whether it suits you and follow the pack instructions.
View the Cyventine 25-day quit program · TGA consumer and product information for Cyventine
WHO tobacco cessation guideline for adults
Answer all six questions to calculate the score.
References
Giulietti F, Filipponi A, Rosettani G, et al. Pharmacological Approach to Smoking Cessation: An Updated Review for Daily Clinical Practice . High Blood Press Cardiovasc Prev. 2020;27(5):349–362. Figure 1 is the source for this flowchart. Table 1 provides the FTND score bands. Open-access full text .
World Health Organization. WHO clinical treatment guideline for tobacco cessation in adults . 2024. Annex 2 covers the 5 A’s and 5 R’s.
US Public Health Service. Treating Tobacco Use and Dependence: 2008 Update . 2008.
Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire . Br J Addict. 1991;86(9):1119–1127.
Pharmaceutical Society of Australia. Nicotine cessation guidelines for pharmacists . December 2025.
Royal Australian College of General Practitioners. Supporting smoking cessation: A guide for health professionals .
Quit. Combination nicotine replacement therapy and nicotine replacement therapy FAQs .
Therapeutic Goods Administration. Australian product and consumer medicine information for Zyban SR (ARTG 75233) and Cyventine (ARTG 522371) .
Lindson N, et al. Pharmacological and electronic cigarette interventions for smoking cessation in adults: component network meta-analyses . Cochrane Database Syst Rev. 2023;CD015226.
Theodoulou A, et al. Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation . Cochrane Database Syst Rev. 2023;CD013308.
Courtney RJ, et al. Effect of Cytisine vs Varenicline on Smoking Cessation: A Randomized Clinical Trial . JAMA. 2021.
Rigotti NA, et al. Cytisinicline for Smoking Cessation: The ORCA Phase 3 Replication Randomized Clinical Trial . JAMA Intern Med. 2025;185(6):648–655.
Cinciripini PM, et al. Smoking Cessation After Initial Treatment Failure With Varenicline or Nicotine Replacement: A Randomized Clinical Trial . JAMA. 2024;331(20):1722–1731.